Dr Glen Reid

Glen is a Senior Research Scientist at ADRI, and established the Institute's cell and molecular biology labs.
  • T1/T2 Working Group
  • Scholarship Review Panel


Glen's research focuses on the identification of new markers and molecular targets for malignant mesothelioma.  Prior to joining ADRI, he was Principal Investigator and Head of RNAi Product Development for Genesis Research & Development Corporation in New Zealand where he led a cancer RNAi discovery program. He was awarded a PhD from the University of Göttingen in Germany, after which completed his postdoctoral studies with Professor Piet Borst at The Netherlands Cancer Institute in Amsterdam, where his main focus was on the characterization of multidrug resistance proteins.

In his spare time, Glen likes to swim until he can't see land.

Research Interests:  

Glen's group focuses on translational studies of the asbestos-related cancer malignant pleural mesothelioma. The group's twin aims are to identify new biomarkers and novel molecular targets for therapy. They have identified a number of microRNAs that are candidate tumour and blood biomarkers for mesothelioma, and a number with the potential to serve as targets for therapeutic intervention. This work is the basis of the current MesomiR-1 trial of a microRNA-based therapy for mesothelioma patients.